EGFR and non-small cell lung carcinoma: Moreover, large-scale prospective studies will be needed to understand the link between the pathogenicity of the rare mutations and therapeutic strategies like EGFR-TKI, to treat some resistant and uncommon EGFR mutations in NSCLC.